Growth Plus Reports Logo.jpg
Post-traumatic Stress Disorder Market is set to Reach US$ 1.51 billion at a CAGR of 4.68% from the forecast period 2023 to 2031 | Growth Plus Reports
13. Februar 2024 01:14 ET | Growth Plus Reports
Pune, Feb. 13, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Post-traumatic Stress Disorder Market is expected to clock US$ 1.51 billion by...
Final Logo-01.png
Post-Traumatic Stress Disorder Therapy Market Demonstrates Strong Growth with a CAGR of 4.7% and Reaches a Value of US$ 1,551.3 million 2032 – By PMI
21. September 2023 13:30 ET | PMI
Covina, Sept. 21, 2023 (GLOBE NEWSWIRE) -- What is Post-Traumatic Stress Disorder Therapy Market? Post-traumatic stress disorder is a condition of mental health that developed in an...
mrf.jpg
Post-Traumatic Stress Disorder Market Size Worth USD 1.60 Billion by 2030 at 4.80% CAGR – Report by Market Research Future (MRFR)
09. Mai 2023 10:25 ET | Market Research Future
New York, USA, May 09, 2023 (GLOBE NEWSWIRE) -- Post-Traumatic Stress Disorder Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR),“Post-Traumatic...
Future Market Insights.png
Global Post-Traumatic Stress Disorder (PTSD) Treatment Market to reach US$ 27.37 billion by 2033; Antidepressants to be Most Consumed | Future Market Insights, Inc. NEWARK, Del, March 10, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Post-Traumatic Stress Disorder (PTSD) Treatment Market is expected to grow at a value of 5% CAGR,...
logo 600X600.png
Global Post-traumatic Stress Disorder Market to Surpass US$ 1536.8 Million by 2030, Says Coherent Market Insights (CMI)
15. Februar 2023 09:30 ET | CMI
Burlingame, Feb. 15, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global post-traumatic stress disorder market is estimated to be valued at US$ 1034.3 million in 2022 and is...
compass_positive_tagline-01.png
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
03. November 2021 08:00 ET | COMPASS Pathways
London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
Author Reflects on 30-Year Career in Prison System in New Memoir
14. September 2020 08:00 ET | WestBow Press
LOS OSOS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Author Arthur H. Mooneyhan, who spent more than three decades working in the U.S. prison system, has published a compelling nonfiction book that...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
18. Juni 2020 07:57 ET | Aptinyx Inc.
EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...